High Rates of Seroprotection and Seroconversion to Vaccine-Preventable Infections in the Early Post–Autologous Stem Cell Transplant Period-Reference-Cited by-同舟云学术

High Rates of Seroprotection and Seroconversion to Vaccine-Preventable Infections in the Early Post–Autologous Stem Cell Transplant Period

Published:2023-09-30 Issue:10 Volume:10 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Hall Victoria G¹²^ORCID,Saunders Natalie R²,Klimevski Emily²,Tennakoon Gayani S²,Khot Amit¹³,Harrison Simon¹³,Worth Leon J¹²,Yong Michelle K¹²⁴,Slavin Monica A¹²⁴,Teh Benjamin W¹²^ORCID

Affiliation:

1. Sir Peter MacCallum Department of Oncology, University of Melbourne , Parkville , Australia

2. Department of Infectious Diseases, Peter MacCallum Cancer Centre , Melbourne , Australia

3. Department of Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital , Melbourne , Australia

4. Department of Infectious Diseases, Royal Melbourne Hospital , Parkville , Australia

Abstract

Abstract In patients early post–autologous stem cell transplant, seroprotection rates were high for Hemophilus influenzae type B and tetanus toxoid (70%–90%) but lower for Streptococcus pneumoniae (30%–50%) including after revaccination. There were high rates of seropositivity (67%–86%) to measles, mumps, and rubella and varicella zoster virus. Durability of protection requires assessment.

Funder

Peter MacCallum Cancer Centre

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofad497/51906617/ofad497.pdf

Reference12 articles.

1. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7);Cordonnier;Lancet Infect Dis,2019

2. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective;Tomblyn;Biol Blood Marrow Transplant,2009

3. Serological response to vaccination after autologous transplantation for multiple myeloma is associated with improved progression-free and overall survival;Merz;Transplant Cell Ther,2021

4. Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance;Palazzo;Biol Blood Marrow Transplant,2018

5. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation;Pandit;Bone Marrow Transplant,2018